Grove Biopharma

About Grove Biopharma

Grove Biopharma is pioneering Bionic Biologics™, a breakthrough synthetic modality for developing novel therapeutics that target intracellular protein-protein interactions. The company aims to create better medicines for patients with cancer, neurodegenerative diseases, and rare disorders by providing protein-scale solutions to disrupt or degrade disease-causing target proteins.

Products & Services

Bionic Biologics™:Hybrid biomolecules integrating biologic and synthetic design for enhanced functionality, cell permeability, and customizable, modular construction to target intracellular protein-protein interactions.

Specialties

Bionic Biologics Synthetic Drug Modality Intracellular Protein-Protein Interactions Therapeutics for Cancer Therapeutics for Neurodegenerative Diseases Therapeutics for Rare Disorders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 30000000 MR: - FA: 30 million FAN: 30000000	D: 2025-04-23 FD: 2025-04-23	7 investors

Series A Latest

2025-04-23

$30.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Geoffrey M. Duyk

Co-Founder, Board Chair & CEO

P

Paul A. Bertin

Co-Founder, President & CTO

R

Robert M. Campbell

CSO

I

Imran Nasrullah

Chief Business Officer

L

Laura Robinson

COO

N

Nathan C. Gianneschi

Scientific Founder, SAB Chair

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

Grove Biopharma Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised